期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CHOP序贯DICE方案与标准CHOP方案治疗高危弥漫大B细胞淋巴瘤的随机对照研究 被引量：4

原文传递
导出
摘要 弥漫大B细胞淋巴瘤（DLBCL）是临床上常见的中度恶性淋巴瘤。虽然CHOP（环磷酰胺、长春新碱、泼尼松、阿霉素）方案一直被认为是标准的一线方案，但是对于IPI评分〉3分的患者远期疗效较差，复发率高。近年来有研究报道DICE（地塞米松、异环磷酰胺、顺铂、足叶乙甙）方案对于中、高度恶性淋巴瘤有较好的疗效，2001年7月至2004年3月我们采用CHOP序贯DICE方案治疗IPI评分〉3的DLBCL患者，并同标准的CHOP方案进行比较，以期找到对晚期高危DLBCL患者更为有效的治疗方法。
作者 房佰俊 李宁 宋永平 李玉富 魏旭东 张袭丽
机构地区 河南省肿瘤医院血液科 河南省肿瘤医院内科
出处 《中华血液学杂志》 CAS CSCD 北大核心 2009年第5期335-337,共3页 Chinese Journal of Hematology
关键词 弥漫大B细胞淋巴瘤 CHOP方案 方案治疗 随机对照研究 DICE方案 标准 高危 序贯
分类号 R686 [医药卫生—骨科学]
  • 相关文献

参考文献11

  • 1Yi PI, Coleman M, Saltz L, et al. Chemotherapy for large cell lymphoma: a status update. Semin Oncol, 1990,17:60-73.
  • 2王文武,欧阳学农,陈樟树,彭永海,解方为,余宗阳.DICE方案与CHOP方案治疗中高度恶性非霍奇金淋巴瘤的随机对照研究[J].中国癌症杂志,2006,16(9):748-750. 被引量：2
  • 3Hornberqer JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-Cell lymphom. Cancer, 2005,103 : 1644-1651.
  • 4Best JH, Hornverger J, Proctor SJ, et al. Cost-effectiveness analysis of rituximab combined with CHOP for treatment of diffuse large B-cell lymphoma. Value Health, 2005,8 : 462470.
  • 5Hill BT, Price LA, Goldie JH. The value of adriamycin in overcoming resistance to methotrexate in cell culture. Eur J Cancer, 1976,12:541-549.
  • 6Teicher BA, Cucchi CA, Lee JB, et al. Alkylating agents: in vitro studies of crossresistance patterns in human cell lines. Cancer Res, 1986, 46: 4379-4383.
  • 7Haim N, Rosenblatt E, Wollner M, et al. Salvage therapy for non- Hodgkin' s lymphoma with a combination of dexamethasone, etopo- side, ifosfamide, and cisplatin. Cancer Chemother Pharmacol, 1992, 30:243-244.
  • 8Biaqi JJ, Herbert KE, Smith C, et al. A phase Ⅱstudy of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma. Leuk Lymphoma, 2005,46 : 197-206.
  • 9Haim N, Ben-Shahar M, Faraggi D, et al. Dexamethasone, etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin ' s lymphoma. Cancer, 1997,80: 1989-1996.
  • 10Haim N, Drumea K, Epelbaum R, et al. Dexamethasone, cytarabine, ifosfamide, and cisplatin as salvage therapy in non- Hodgkin' s lymphoma. Am J Clin Oncol, 1999,22:47-50.

二级参考文献7

  • 1Messori A,Vaiani M,Trippoli S,et al.Survial in patients with intermediate or high grade non-Hodgkin's lymphoma:meta-analysis of randomized studies comparing third generation regimens with CHOP[J].Cancer,2001,84 (3):303 ～307.
  • 2Haim N,Rosenblatt E,Wollner M,et al.Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone,etoposide,ifosfamide and cisplatin[J].Cancer Chemother Pharmacol,1992,30 (3):243-244..
  • 3Multani P,White CA,Grillo-Lopez A.Non-Hodgkin's lymphoma:review of conventional treatments[J].Curr Pharm Biotechnol,2001,2 (4):279 ～291..
  • 4Gisselbrecht C,Mounier N.Improing second-line therapy in aggressive non-Hodgkin's lymphoma[J].Semin Oncol,2004,31 (1 Suppl 2):12-16..
  • 5Kimby E,Brandt,Nygren P,et al.A systematic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma[J].Acta Oncol,2001,40 (2-3):198-212..
  • 6Loehrer PJ Sr,Laurer R,Roth B J,et al.Salvage therapy in recurrent germ cell cancer:ifosfamide and cisplatin plus either vinblastine or etoposide[J].Ann Intern Med,1998,109 (7):540-546..
  • 7Coleman M,Leonard J,Shuster MW,et al.DICE (dexamethasone,ifosfamide,cisplatin,etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL)[J].Eur J Haematol Suppl,2001,(64):41-45..

共引文献1

同被引文献29

  • 1张晓艳,李建勇,吴汉新,陆化,钱思轩,吴雨洁,徐卫,洪鸣,张闰.利妥昔单抗联合自体外周血干细胞移植治疗非霍奇金淋巴瘤[J].中国新药与临床杂志,2006,25(7):541-544. 被引量：3
  • 2王文武,欧阳学农,陈樟树,彭永海,解方为,余宗阳.DICE方案与CHOP方案治疗中高度恶性非霍奇金淋巴瘤的随机对照研究[J].中国癌症杂志,2006,16(9):748-750. 被引量：2
  • 3曹亚兵,王树森,黄慧强,徐光川,何友兼,管忠震,林桐榆.原发性乳腺淋巴瘤27例临床分析并文献复习[J].癌症,2007,26(1):84-89. 被引量：16
  • 4Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prog- nostic Index (NCCN- IPI) for patients with diffuse large B- cell lym- phoma treated in the rituximab era[J ]. Blood, 2014,123 (6): 837 -842.
  • 5Liu MT, Hsieh CY, Wang AY, et al. Primary breast lymphoma: apooled analysis of prognostic factors and survival in 93 cases[J]. Ann Saudi med, 2005, 25(4): 288-293.
  • 6Hosein PJ, Maragulia JC, Salzberg MP, et al. A multicentrestudy of primary breast diffuse large B- cell lymphoma in therituximab era[j]. Br J Haematol, 2014,165(3): 358-363.
  • 7Ou CW, Shih LY, Wang PN, et al. Primary breast lymphoma: asingle-institute experience in Taiwan [J]. Biomed J, 2014, 37.5): 321-325.
  • 8Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis ofextranodal lymphomas [J]. Cancer, 1972,29( 1): 252-260.
  • 9Rismanchi S, Muhammadnejad S,Amanpour S, et al. Firstpathological study of canine primary breast lymphoma and thedescription of its clinicopathological characteristics as an animalmodel for human primary breast lymphoma [J]. Biomed Rep,2015,3(1): 75-77.
  • 10Ryan G, Martinelli G, Kuper-Hommel M, et al. Primary diffuselarge B- cell lymphoma of the breast: prognostic factors andoutcomes of a study by the International Extranodal LymphomaStudy Group [J]. Ann Oncol, 2008,19(2): 233-241.

引证文献4

二级引证文献19

中华血液学杂志
2009年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部